Answers are grounded in this paper and cite their sources.
Abstract Deep brain stimulation (DBS) has emerged as a powerful neuromodulation approach for treating a range of otherwise treatment-resistant neurological and neuropsychiatric disorders. Its clinical efficacy is well established in Parkinson's disease and essential tremor, and growing evidence supports its use in obsessive-compulsive disorder and major depressive disorder. More recently, DBS has also been explored in Alzheimer's disease, though with variable outcomes. Despite its expanding clinical application, the neurochemical mechanisms through which DBS exerts therapeutic effects remain incompletely understood. Elucidating these mechanisms is critical for optimizing stimulation parameters, enhancing efficacy, and extending DBS to new indications. This review synthesizes current knowledge on the neurochemical effects of DBS across these disorders. We first provide an overview of the primary methods for measuring neurochemical changes, namely microdialysis and voltammetry, in both preclinical and clinical settings. We then review how DBS influences key neurotransmitter systems, including dopaminergic, glutamatergic, GABAergic, and serotonergic pathways, across the aforementioned conditions. Finally, we highlight methodological challenges, gaps in current understanding, and promising directions for future research aimed at clarifying the neurochemical underpinnings of DBS.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: